How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.10. The company earned $29.31 million during the quarter, compared to the consensus estimate of $29.13 million. During the same period in the prior year, the firm earned ($0.65) earnings per share.

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Nicox (NICXF) , Micron Technology (MU) , Melinta Therapeutics (MLNT) , BioMarin Pharmaceutical (BMRN) , Gilead Sciences (GILD) , Puma Biotechnology (PBYI) , NVIDIA (NVDA) , Wells Fargo & Company (WFC) and Alibaba Group (BABA) .

NASDAQ:AERI

Aerie Pharmaceuticals (AERI) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free AERI Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $15.25
▼
$15.25
50-Day Range: $15.18
▼
$15.25
52-Week Range: $4.81
▼
$15.37

Volume: 600 shs
Average Volume: 974,748 shs
Market Capitalization: $753.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Aerie Pharmaceuticals alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Aerie Pharmaceuticals Stock (NASDAQ:AERI)

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

AERI Stock News Headlines

February 29, 2024 | uk.finance.yahoo.com

20 Countries With Worst Vision Problems

February 21, 2024 | finance.yahoo.com

Paratus Sciences Appoints Theresa Heah, M.D., M.B.A. as Chief Executive Officer

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

January 12, 2024 | msn.com

Justin Timberlake is ready to Rock Your Body for one night only in Memphis, and for free

January 10, 2024 | msn.com

Alcon’s dry eye drug achieves primary endpoints in Phase III trials

January 8, 2024 | finanznachrichten.de

Curative Biotechnology, Inc.: Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors

January 8, 2024 | markets.businessinsider.com

Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors

December 15, 2023 | finance.yahoo.com

Glaucoma Therapeutics Market Size Projected to Reach USD 13.5 billion by 2031, With 5.5% CAGR: Transparency Market Research, Inc.

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

November 28, 2023 | finance.yahoo.com

Global Over the Counter (OTC) Drugs Market Size to Grow USD 265 Billion by 2032 | CAGR of 5.0%

November 25, 2023 | nypost.com

Aerie’s Black Friday Sale is here —Save 40% off sitewide for a limited time

November 23, 2023 | finance.yahoo.com

Netarsudil for Fuchs Endothelial Corneal Dystrophy (FECD), 2019-2023 Emerging Drug Insights and Forecasts to 2032

November 23, 2023 | finance.yahoo.com

Global Glaucoma Treatment Market Size To Grow USD 10.5 Billion by 2032 | CAGR of 5.0%

October 27, 2023 | finanznachrichten.de

Opthea Limited: Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO

October 27, 2023 | markets.businessinsider.com

Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO

October 23, 2023 | finance.yahoo.com

Retinal Vein Occlusion Market to Exhibit Considerable Growth at a CAGR of ~6% During the Study Period (2019–2032) | DelveInsight

September 25, 2023 | uk.finance.yahoo.com

Rising Glaucoma Cases Forecast a Strong Optic Nerves Disorder Treatment Market

September 13, 2023 | benzinga.com

Optic Nerves Disorder Treatment Market Rises: North America Takes the Helm

August 25, 2023 | time.com

Aerie Promo Codes

August 24, 2023 | uk.finance.yahoo.com

Angina Pectoris Drugs Global Market Report 2023

August 24, 2023 | uk.finance.yahoo.com

Ocular Hypertension Treatment Global Market Report 2023

July 18, 2023 | msn.com

Alcon (ALC) Gains From Robust Contact Lense Sales, Launches

June 27, 2023 | finance.yahoo.com

VillageMD Welcomes Richard Rubino as Chief Financial Officer

June 22, 2023 | marketwatch.com

The Glaucoma Therapeutics market's size, share, and revenue will be thoroughly examined, with an anticipated CAGR of 13% increase from 2023 to 2030.

June 22, 2023 | uk.finance.yahoo.com

I-Mab Announces the Appointment of Raj Kannan as CEO

June 22, 2023 | markets.businessinsider.com

I-Mab Names Raj Kannan CEO - Quick Facts

June 8, 2023 | uk.finance.yahoo.com

Ophthalmic Drugs Global Market Report 2023

See More Headlines

Receive AERI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:AERI
CUSIP: N/A
CIK: 1337553
Web: www.aeriepharma.com
Phone: (919) 237-5300
Fax: 949-526-8787
Employees: 376
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.77)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-74,810,000.00
Net Margins: -17.09%
Pretax Margin: -16.47%
Return on Equity: N/A
Return on Assets: -2.00%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.27
Quick Ratio: 1.92

Sales & Book Value

Annual Sales: $194.13 million
Price / Sales: 3.88
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.32) per share
Price / Book: -4.59

Miscellaneous

Outstanding Shares: 49,417,000
Free Float: 47,223,000
Market Cap: $753.61 million
Optionable: Optionable
Beta: -0.06

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Raj Kannan (Age 58)
CEO, Principal Financial Officer & Director
Comp: $753.49k
Dr. Casey C. Kopczynski Ph.D. (Age 61)
Co-Founder, Chief Innovation Officer & Head of Research and External Innovation
Comp: $685.06k
Mr. John W. LaRocca Esq. (Age 57)
Gen. Counsel & Sec.
Comp: $676.62k
Mr. Peter F. Lang (Age 50)
Chief Financial Officer
Dr. Michelle Senchyna Ph.D.
Head of Clinical Devel. & Operations
Mr. Jeffrey M. Calabrese CPA (Age 55)
VP of Fin. & Principal Accounting Officer
Ms. Carolyn McAuliffe
Sr. Director of Communications
Ms. Wanda Francies
Head of HR
Mr. Marvin J. Garrett (Age 71)
Head of Regulatory Affairs & Quality Assurance
Mr. Craig R. Skenes
Head of Bus. Devel.

Key Competitors

View All Competitors

AERI Stock Analysis - Frequently Asked Questions

How were Aerie Pharmaceuticals' earnings last quarter?: Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.10. The company earned $29.31 million during the quarter, compared to the consensus estimate of $29.13 million. During the same period in the prior year, the firm earned ($0.65) earnings per share.
What other stocks do shareholders of Aerie Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

This page (NASDAQ:AERI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aerie Pharmaceuticals (AERI) Stock Price, News & Analysis

About Aerie Pharmaceuticals Stock (NASDAQ:AERI)

AERI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

AERI Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info